This article has been co-published with permission in EP Europace and EuroIntervention. All
rights reserved. VC 2019 the European Heart Rhythm Association and the European …

Exclusion of the left atrial appendage to reduce thromboembolic risk related to atrial
fibrillation was first performed surgically in 1949. Over the past 2 decades, the field of …

Chronic oral anticoagulation therapy is the standard therapy for preventing thromboembolic
events in patients with atrial fibrillation. However, oral anticoagulation has been associated …

Atrial fibrillation (AF) is a worldwide epidemic associated with significant morbidity and
mortality, often due to disabling or fatal thromboembolic stroke. Oral anticoagulation is highly …

Aims: The aim of our study was to evaluate the prevalence of left atrial cavity and
appendage thrombosis in patients undergoing cardioversion for non-valvular atrial …

Background: Left atrial appendage closure is an established therapy in patients with atrial
fibrillation. Although device-related thrombosis (DRT) is relatively rare, it is potentially linked …

According to clinical studies, around one third of patients with atrial fibrillation (AF) will suffer
a stroke during their lifetime. Between 70 and 90% of these strokes are caused by thrombus …

Objectives: This study sought to evaluate the feasibility, safety, and efficacy of intracardiac
echocardiography (ICE)–guided versus transesophageal echocardiography (TEE)–guided …

The optimal antithrombotic strategy following left atrial appendage occlusion (LAAO) is not
yet clearly established. Low-dose non-vitamin K antagonist oral anticoagulants (NOAC) …

Left atrial appendage (LAA) closure for stroke prevention in the setting of non-valvular atrial
fibrillation is an alternative to oral anticoagulation in patients with increased bleeding risk. It …